Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 6
Submit an article Journal homepage
602
Views
3
CrossRef citations to date
0
Altmetric
Letter to the Editor

‘Real-world’ Australian experience of pomalidomide for relapsed and refractory myeloma

Ashleigh ScottPrincess Alexandra Hospital, Woollongabba, Brisbane, Australia; ;University of Queensland, St Lucia, Brisbane, Australia; ;Royal Brisbane and Women’s Hospital, Herston, Brisbane, Australia; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-5574-6713View further author information
ORCID Icon,
Nicholas WeberRoyal Brisbane and Women’s Hospital, Herston, Brisbane, Australia; View further author information
,
Campbell TileyGosford Hospital, Gosford, New South Wales, Australia; View further author information
,
Kerry TaylorIcon Cancer Care, South Brisbane, Australia; View further author information
,
John TaperNepean Hospital, Nepean, Sydney, Australia; View further author information
,
Simon HarrisonPeter MacCallum Cancer Centre, Melbourne, Australia; View further author information
,
Kah-Lok ChanPeter MacCallum Cancer Centre, Melbourne, Australia; View further author information
,
Richard StarkPort Macquarie Base Hospital, Port Macquarie, New South Wales, Australia; View further author information
,
Cindy LeeRoyal Adelaide Hospital, Queen Elizabeth Hospital, Adelaide, Australia; View further author information
,
Kirk MorrisRoyal Brisbane and Women’s Hospital, Herston, Brisbane, Australia; View further author information
,
P. Joy HoRoyal Prince Alfred Hospital, Sydney, Australia; View further author information
,
Anthony DoddsSt Vincent’s Hospital, Sydney, Australia; View further author information
,
Sundra RamanathanSt George Hospital, Kogarah, Sydney, Australia; View further author information
,
Raj RamakrishnaSouthern Sydney Haematology, Kogarah, Sydney, Australia; View further author information
,
Anne-Marie WatsonLiverpool Hospital, Liverpool, Sydney, Australia; View further author information
,
Bradley AugustonSir Charles Gairdner Hospital, Perth, Australia; View further author information
,
Fiona KwokWestmead Hospital, Sydney, Australia; View further author information
,
Hang QuachSt Vincent’s Hospital, Melbourne, Australia; View further author information
,
Pauline WarburtonWollongong Hospital, Wollongong, New South Wales, Australia; View further author information
,
Philip RowlingsCalvary Mater Hospital, Newcastle, New South Wales, AustraliaView further author information
&
Peter MolleePrincess Alexandra Hospital, Woollongabba, Brisbane, Australia; ;University of Queensland, St Lucia, Brisbane, Australia; View further author information
 show all
Pages 1514-1516 | Received 11 Aug 2017, Accepted 22 Sep 2017, Published online: 12 Oct 2017

References

  • Chanan-Khan AA, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013;3:e143.
  • Lacy MQ, McCurdy AR. Pomalidomide. Blood. 2013;122:2305–2309.
  • Liu Y, Huang X, He X, et al. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. FASEB J. 2015;29:4829–4839.
  • San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (mm-003): A randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066.
  • Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346.
  • Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548.
  • Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420.
  • Maciocia N, Melville A, Cheesman S, et al. Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. Br J Haematol. 2017;176:908–917.
  • Sriskandarajah P, Pawlyn C, Mohammed K, et al. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a “real-world” study: the royal marsden hospital experience. Leuk Lymphoma. 2017;58:494–497.
  • Ludwig H, Miguel JS, Dimopoulos MA, et al. International myeloma working group recommendations for global myeloma care. Leukemia. 2014;28:981–992.
  • Kahan BC, Rehal S, Cro S. Risk of selection bias in randomised trials. Trials. 2015;16:405.
  • Estey E. Do commonly used clinical trial designs reflect clinical reality? Haematologica. 2009;94:1435–1439.
  • Sharpe N. Clinical trials and the real world: selection bias and generalisability of trial results. Cardiovasc Drugs Ther. 2002;16:75–77.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.